Scorpion Sting Envenomation Clinical Trial
Official title:
Establishment of Natural History of Scorpion Envenomation in the Absence of Antivenom Treatment in Pediatric Patients
This retrospective study was conducted to collect data from approximately 100 patients from 6 months to 18 years of age who were stung by a scorpion but were not treated with antivenom. The study consisted of a review of hospital records of patients who were admitted for intensive care management of scorpion envenomation, at the only two hospitals in North America known to admit children routinely for scorpion sting management without antivenom. The standard of care consisted of symptomatic and supportive care, including airway maintenance, fluid and electrolyte support and, if necessary, sedation.
The study objective was to document the clinical syndrome of scorpion envenomation in the
absence of antivenom treatment in pediatric patients. This was done to establish historical
control data on the time from sting to the time of resolution of signs of envenomation. These
historical control data are intended to be used for comparison with Alacramyn treated
patients in two prospective studies being conducted in Mexico and the U.S.for which a control
population could not otherwise be established.
The total duration of clinically important systemic signs of envenomation was determined
based upon overall investigator assessment of the last signs of any respiratory compromise,
any pathological agitation or other indicator of continuing illness (e.g., continuing need
for sedative administration).
To facilitate comparison of these historical data with prospective open label trials,
periodic assessments of the overall presence or absence of clinically important signs was
performed. Periodic assessments were also performed for each individual component indicator
of respiratory compromise and of pathological agitation, when available.
A research nurse reviewed hospital discharge diagnoses for all pediatric charts coded for
"scorpion sting". For these cases demographic, diagnostic, and therapeutic data were entered
on the case report form (CRF) as well as data necessary to assess compliance with study
inclusion and exclusion criteria.
A physician subinvestigator reviewed the research nurse's findings for the key outcome
indicators, which consisted of clinically important systemic signs of scorpion envenomation
and adjunctive sedation treatment (dose and timing of dose) when medical judgment was
required.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00624078 -
Treatment Protocol for Use of Anascorp™ in Patients With Scorpion Sting Envenomation
|
Phase 2/Phase 3 | |
Completed |
NCT01599923 -
Open Label Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation
|
Phase 3 | |
Completed |
NCT00685230 -
Double-Blind, Alacramyn® vs. Placebo in Pediatric Patients
|
Phase 2/Phase 3 | |
Completed |
NCT01599936 -
Open Label Clinical Trial of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation
|
Phase 3 |